Venture Life Group PLC UltraDEX Patent Grants and Distribution Update (8825F)

TIDMVLG

RNS Number : 8825F

Venture Life Group PLC

23 May 2017

Venture Life Group plc

("Venture Life" or the "Company")

UltraDEX Patent Grants and Distribution Update

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces it has been granted patents in Japan, Indonesia, Australia and Mexico for its UltraDEX Sensitive range. These new recent patent grants add to the existing patents already granted in the USA, UK, South Africa and New Zealand for this innovative product range. Venture Life also has patent applications pending in many other jurisdictions, including the EU.

The aforementioned range of products contains a multicomponent composition and includes specific ingredients to reduce sensitivity and provide 12 hours of fresh breath. The UltraDEX range of products is manufactured at Venture Life's development facility in Italy.

Domestically, Venture Life's has agreed with Boots Chemists ("Boots") to list two new additional UltraDEX products, increasing the range of UltraDEX products stocked in store from eight to ten. As a result of these new listings and further distribution gains, shelf space presence will further increase from July onwards. The Board believes this further validates Venture Life's relationship with this key partner in the UK, and shows the continuing strength of the UltraDEX brand.

Jerry Randall, CEO of Venture Life, commented: "In Q1 2017, we ran a second successful UK advertising campaign that saw the UltraDEX brand once again featured on tube cards and radio stations across London and the South East, alongside promotional activity in key retailers. We are planning further activities in 2017 combined with a continued brand refresh and future product development. I am particularly delighted to see the further validation of the UltraDEX range in Boots, listing two additional products in the range. The progress we are making is testament to our strong leadership team and excellent support network, and reaffirms our strategic direction for the brand that we set out at the time of its acquisition last year."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

For further information please contact:

 
                                                               +44 (0) 1344 
 Venture Life Group PLC                                              742870 
 Jerry Randall, Chief Executive Officer 
 Adrian Crockett, Chief Financial Officer 
 
 
 Northland Capital Partners Limited                              +44 (0) 20 
  (Nominated Adviser and Joint Broker)                            3861 6625 
 Matthew Johnson / Edward Hutton / Margarita 
  Mitropoulou (Corporate Finance) 
 Bob Pountney / John Howes (Corporate 
  Broking) 
 
 
 Turner Pope Investments (TPI) Ltd (Joint                        +44 (0) 20 
  Broker)                                                         3621 4120 
 James Pope / Ben Turner 
 
 
 Walbrook PR                                    [e-mail] 
                                                 or + 44 (0) 20 7933 8780 
 Anna Dunphy / Paul McManus                      [phone] / +44 
                                                           (0) 7876 741 001 
 
 
 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its development and manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVEEFIFFID

(END) Dow Jones Newswires

May 23, 2017 02:00 ET (06:00 GMT)